Trial Search Results

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

This phase I trial will assess primarily the safety and secondarily the anti-inflammatory and anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and other inflammatory disorders of the retina, choroid and vitreous.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Targeted Therapy Technologies, LLC

Stanford Investigator(s):


  • Drug: Episcleral Celecoxib


Phase 1


Inclusion Criteria:

   - Age >= 18 years;

   - Visual acuity letter score in study eye < 70 and ≥ 25 letters (approximate Snellen
   equivalent 20/32 to 20/320);

   - Ophthalmoscopic evidence of center-involved macular edema, within the central subfield
   (CSF); • Inflammatory disorders of the sclera, choroid, retina or vitreous

Exclusion Criteria:

   - Inability to understand informed consent, cooperate with testing or return to follow
   up visits;

   - Pregnant or lactating women;

   - Co-existent ocular disorder of the cornea, lens or media that will interfere with
   assessment of safety or efficacy.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amy Dennis, RN